Phase 1 ATLAS trial to evaluate TK-6302 in patients with advanced PRAME-positive solid tumors authorized for initiation
Application deadline: 3 March 2026
Partnership with leading nuclear medicine specialist enables advancing pipeline of wholly-owned Radio-DARPin therapeutics for imaging and therapeutic radio-isotopes, including Actinium-225 (225Ac)
Whether we tend to eat carbohydrates or fats in the morning may help determine how our metabolism works. Prof. Olga Ramich from the German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE) and Charité – Universitätsmedizin Berlin and her team…
Background: Long-term health effects associated with SARS-CoV-2 pose major challenges for public health and health research worldwide.
Methods: Based on an ongoing literature review, a narrative review (as of June 2025) on the epidemiology and…
- U.S. Investigational New Drug (IND) applications for radiotheranostic pair PentixaFor and PentixaTher became active following completion of the FDA 30-day review period.
- Proposed phase I/II trial designed to confirm the suitability of…
Researchers at the Max Delbrück Center have uncovered how a bacterial metabolite produced in the gut regulates heart function through specific brain cells. The findings, published in “Circulation Research,” reveal a new gut-brain-heart axis and point…
An international research group has examined how many people are affected by preclinical and clinical obesity and what health risks are associated with this. The team led by Prof. Matthias Schulze from the German Institute of Human Nutrition…
Despite improved inflammation control 50 % of patients with rheumatic disease suffer from persistent exhaustion or fatigue
With the establishment of an ARC Innovation Center, Charité – Universitätsmedizin Berlin and the Berlin Institute of Health at Charité (BIH) are creating a new organizational framework to advance medical innovations rapidly and in a targeted manner.…
